HRP970350B1 - Substituted indazole analogs - Google Patents

Substituted indazole analogs

Info

Publication number
HRP970350B1
HRP970350B1 HR970350A HRP970350A HRP970350B1 HR P970350 B1 HRP970350 B1 HR P970350B1 HR 970350 A HR970350 A HR 970350A HR P970350 A HRP970350 A HR P970350A HR P970350 B1 HRP970350 B1 HR P970350B1
Authority
HR
Croatia
Prior art keywords
substituted indazole
indazole analogs
analogs
substituted
indazole
Prior art date
Application number
HR970350A
Other languages
English (en)
Inventor
Anthony Marfat
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HRP970350A2 publication Critical patent/HRP970350A2/xx
Publication of HRP970350B1 publication Critical patent/HRP970350B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR970350A 1996-06-25 1997-06-25 Substituted indazole analogs HRP970350B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2038596P 1996-06-25 1996-06-25

Publications (2)

Publication Number Publication Date
HRP970350A2 HRP970350A2 (en) 1998-06-30
HRP970350B1 true HRP970350B1 (en) 2003-04-30

Family

ID=21798354

Family Applications (1)

Application Number Title Priority Date Filing Date
HR970350A HRP970350B1 (en) 1996-06-25 1997-06-25 Substituted indazole analogs

Country Status (43)

Country Link
US (1) US6040329A (de)
EP (1) EP0912558B1 (de)
JP (1) JP3152940B2 (de)
KR (1) KR20000022516A (de)
CN (1) CN1080260C (de)
AP (1) AP1025A (de)
AR (1) AR007456A1 (de)
AT (1) ATE244713T1 (de)
AU (1) AU716376B2 (de)
BG (1) BG64052B1 (de)
BR (1) BR9712782A (de)
CA (1) CA2258285C (de)
CO (1) CO4900056A1 (de)
CZ (1) CZ423398A3 (de)
DE (1) DE69723447T2 (de)
DK (1) DK0912558T3 (de)
DZ (1) DZ2254A1 (de)
EA (1) EA002274B1 (de)
ES (1) ES2201299T3 (de)
GT (1) GT199700075A (de)
HK (1) HK1018700A1 (de)
HN (1) HN1997000079A (de)
HR (1) HRP970350B1 (de)
HU (1) HUP9903009A3 (de)
ID (1) ID18579A (de)
IL (1) IL127036A (de)
IS (1) IS4910A (de)
MA (1) MA24225A1 (de)
MY (1) MY116915A (de)
NO (1) NO986103L (de)
NZ (1) NZ332752A (de)
OA (1) OA10934A (de)
PA (1) PA8432301A1 (de)
PL (1) PL330974A1 (de)
PT (1) PT912558E (de)
SI (1) SI0912558T1 (de)
SK (1) SK176598A3 (de)
TN (1) TNSN97108A1 (de)
TR (1) TR199802685T2 (de)
TW (1) TW434237B (de)
WO (1) WO1997049702A1 (de)
YU (1) YU60198A (de)
ZA (1) ZA975581B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2258728C (en) * 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
CA2264798A1 (en) * 1996-09-04 1998-03-12 Pfizer Inc. Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
CA2309175A1 (en) * 1997-11-04 1999-05-14 Pfizer Products Inc. Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
CA2395196C (en) * 1999-12-23 2006-02-21 Icos Corporation Cyclic amp-specific phosphodiesterase inhibitors
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
US7153871B2 (en) 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
JP4535680B2 (ja) * 2001-04-16 2010-09-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 新規１ｈ−インダゾール化合物
CA2469939C (en) 2001-12-14 2012-06-19 Applied Research Systems Ars Holding N.V. Method of inducing ovulation using a non-polypeptide camp level modulator
CN101423497A (zh) * 2002-07-19 2009-05-06 记忆药物公司 作为磷酸二酯酶4抑制剂的6-氨基-1h-吲唑和4-氨基苯并呋喃化合物
AU2003256616B2 (en) 2002-07-19 2009-08-27 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
WO2004046113A2 (en) * 2002-11-19 2004-06-03 Memory Pharmaceuticals Corporation Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors
KR20060005375A (ko) * 2003-04-18 2006-01-17 메모리 파마슈티칼스 코포레이션 포스포디에스테라제 4 억제제로서의 피라졸 유도체
US20090048255A1 (en) * 2003-07-21 2009-02-19 Schumacher Richard A Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
JP2008516964A (ja) 2004-10-15 2008-05-22 メモリー ファーマシューティカルス コーポレーション ホスホジエステラーゼ４阻害剤としてのピラゾール誘導体
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
EP1891060A2 (de) * 2005-05-30 2008-02-27 Ranbaxy Laboratories Limited 3-indazolyl-isoxazoline derivate als typ-iv phosphodiesterase inhibitoren
EP2275095A3 (de) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
US7781460B2 (en) 2005-09-05 2010-08-24 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-IV
EP1934219A1 (de) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituierte pyrazolo-[3,4-b]-pyridine als phosphodiesterase-inhibitoren
EP2377530A3 (de) 2005-10-21 2012-06-20 Braincells, Inc. Modulation von Neurogenese durch PDE-Hemmung
EP2314289A1 (de) 2005-10-31 2011-04-27 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
AU2008224541B2 (en) 2007-03-14 2013-08-22 Sun Pharmaceutical Industries Limited Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
WO2010003084A2 (en) * 2008-07-02 2010-01-07 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011051342A1 (en) * 2009-10-30 2011-05-05 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
EP2804603A1 (de) 2012-01-10 2014-11-26 President and Fellows of Harvard College Betazellen-replikation für promoterverbindungen und verwendungsverfahren dafür
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
WO2015166370A1 (en) 2014-04-28 2015-11-05 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
KR20220167441A (ko) * 2021-06-11 2022-12-21 주식회사 메타센테라퓨틱스 신규한 인돌 유도체 및 이의 최종당화산물 관련 질환의 치료 용도
KR20220167804A (ko) * 2021-06-11 2022-12-22 주식회사 메타센테라퓨틱스 인돌 유도체를 포함하는 최종당화산물 관련 질환의 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB753573A (en) * 1953-06-17 1956-07-25 Ici Ltd New dyestuffs intermediates
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
TW223004B (de) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
US5552438A (en) * 1992-04-02 1996-09-03 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US5554620A (en) * 1993-09-14 1996-09-10 Sterling Winthrop Inc. Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof
JPH07215952A (ja) * 1993-12-06 1995-08-15 Otsuka Pharmaceut Factory Inc カテコール誘導体
CN1050129C (zh) * 1994-10-20 2000-03-08 美国辉瑞有限公司 二环四氢吡唑并吡啶和其作为药物的应用

Also Published As

Publication number Publication date
NZ332752A (en) 2001-04-27
AU716376B2 (en) 2000-02-24
JPH11514668A (ja) 1999-12-14
ES2201299T3 (es) 2004-03-16
TW434237B (en) 2001-05-16
TNSN97108A1 (fr) 2005-03-15
MA24225A1 (fr) 1997-12-31
EA199801047A1 (ru) 1999-06-24
EA002274B1 (ru) 2002-02-28
DE69723447T2 (de) 2003-12-24
AU2785797A (en) 1998-01-14
BG64052B1 (bg) 2003-11-28
TR199802685T2 (xx) 1999-03-22
HN1997000079A (es) 1997-12-26
IL127036A0 (en) 1999-09-22
DK0912558T3 (da) 2003-08-18
PT912558E (pt) 2003-11-28
CA2258285C (en) 2002-11-26
HUP9903009A3 (en) 2002-01-28
MY116915A (en) 2004-04-30
YU60198A (sh) 1999-09-27
ATE244713T1 (de) 2003-07-15
EP0912558A1 (de) 1999-05-06
BG103056A (en) 1999-10-29
CA2258285A1 (en) 1997-12-31
ZA975581B (en) 1998-12-24
CZ423398A3 (cs) 1999-12-15
EP0912558B1 (de) 2003-07-09
AR007456A1 (es) 1999-10-27
DZ2254A1 (fr) 2002-12-18
PA8432301A1 (es) 1999-12-27
ID18579A (id) 1998-04-23
HK1018700A1 (en) 1999-12-30
PL330974A1 (en) 1999-06-21
AP9701020A0 (en) 1997-07-31
SK176598A3 (en) 2000-06-12
SI0912558T1 (en) 2003-10-31
JP3152940B2 (ja) 2001-04-03
IS4910A (is) 1998-11-27
CO4900056A1 (es) 2000-03-27
IL127036A (en) 2001-06-14
OA10934A (en) 2002-02-18
NO986103D0 (no) 1998-12-23
KR20000022516A (ko) 2000-04-25
WO1997049702A1 (en) 1997-12-31
DE69723447D1 (de) 2003-08-14
HUP9903009A2 (hu) 2000-05-28
NO986103L (no) 1998-12-23
BR9712782A (pt) 1999-12-07
HRP970350A2 (en) 1998-06-30
GT199700075A (es) 1998-12-04
CN1223651A (zh) 1999-07-21
US6040329A (en) 2000-03-21
AP1025A (en) 2001-11-19
CN1080260C (zh) 2002-03-06

Similar Documents

Publication Publication Date Title
HRP970350B1 (en) Substituted indazole analogs
ZA977903B (en) Indazole derivatives
ZA9510554B (en) Substituted 1H-imidazoles
HU9603082D0 (en) Neurokinine (tachykinine) antagonists
EP0778836A4 (de) Substituierte 9-alkyladenine
GB9607120D0 (en) Compounds
EP0996458A4 (de) Sandramycin analoge
HU9502378D0 (en) Substituted biphenyl-oxazolinones
ZA954095B (en) Substituted 3-phenylpyrazoles
GB9602326D0 (en) Compounds
ZA956011B (en) Substituted triazolylmethylphenylnaphthyridones
ZA954546B (en) Substituted 3-phenylpyrazoles
ZA972591B (en) Substituted 1-methyl-3-benzyluracils
ZA9711235B (en) Substituted pyrazol-3-ylbenzazoles
PL312691A1 (en) New substituted benzyimidazole
ZA951092B (en) Substituted oxazacycloalkenes
GB9606933D0 (en) Compounds
ZA95887B (en) Substituted pyrazoline
ZA952379B (en) Substituted pyrazoline
ZA956706B (en) Substituted biphenyloxazolines
SG33624A1 (en) Substituted 1H-imidazoles
AU128357S (en) Jumper leads
GB9600624D0 (en) Compounds
GB9607218D0 (en) Compounds
GB9607739D0 (en) Compounds

Legal Events

Date Code Title Description
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
A1OB Publication of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20020625

Year of fee payment: 6

ODBC Application rejected